-
Something wrong with this record ?
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
J. van Prehn, E. Reigadas, EH. Vogelzang, E. Bouza, A. Hristea, B. Guery, M. Krutova, T. Norén, F. Allerberger, JE. Coia, A. Goorhuis, TM. van Rossen, RE. Ooijevaar, K. Burns, BR. Scharvik Olesen, S. Tschudin-Sutter, MH. Wilcox, MJGT....
Language English Country Great Britain
Document type Journal Article
- MeSH
- Anti-Bacterial Agents * therapeutic use MeSH
- Clostridioides difficile MeSH
- Adult MeSH
- Fidaxomicin MeSH
- Clostridium Infections * diagnosis drug therapy MeSH
- Humans MeSH
- Antibodies, Monoclonal MeSH
- Recurrence MeSH
- Broadly Neutralizing Antibodies MeSH
- Practice Guidelines as Topic * MeSH
- Societies, Medical MeSH
- Vancomycin MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
SCOPE: In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014. The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as faecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, prompted the ESCMID study group on C. difficile (ESGCD) to update the 2014 treatment guidance document for CDI in adults. METHODS AND QUESTIONS: Key questions on CDI treatment were formulated by the guideline committee and included: What is the best treatment for initial, severe, severe-complicated, refractory, recurrent and multiple recurrent CDI? What is the best treatment when no oral therapy is possible? Can prognostic factors identify patients at risk for severe and recurrent CDI and is there a place for CDI prophylaxis? Outcome measures for treatment strategy were: clinical cure, recurrence and sustained cure. For studies on surgical interventions and severe-complicated CDI the outcome was mortality. Appraisal of available literature and drafting of recommendations was performed by the guideline drafting group. The total body of evidence for the recommendations on CDI treatment consists of the literature described in the previous guidelines, supplemented with a systematic literature search on randomized clinical trials and observational studies from 2012 and onwards. The Grades of Recommendation Assessment, Development and Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence. The guideline committee was invited to comment on the recommendations. The guideline draft was sent to external experts and a patients' representative for review. Full ESCMID endorsement was obtained after a public consultation procedure. RECOMMENDATIONS: Important changes compared with previous guideline include but are not limited to: metronidazole is no longer recommended for treatment of CDI when fidaxomicin or vancomycin are available, fidaxomicin is the preferred agent for treatment of initial CDI and the first recurrence of CDI when available and feasible, FMT or bezlotoxumab in addition to standard of care antibiotics (SoC) are preferred for treatment of a second or further recurrence of CDI, bezlotoxumab in addition to SoC is recommended for the first recurrence of CDI when fidaxomicin was used to manage the initial CDI episode, and bezlotoxumab is considered as an ancillary treatment to vancomycin for a CDI episode with high risk of recurrence when fidaxomicin is not available. Contrary to the previous guideline, in the current guideline emphasis is placed on risk for recurrence as a factor that determines treatment strategy for the individual patient, rather than the disease severity.
Austrian Agency for Health and Food Safety Vienna Austria
Department of Clinical Microbiology Beaumont Hospital Dublin Ireland
Department of Clinical Microbiology Royal College of Surgeons in Ireland Dublin Ireland
Department of Medical Microbiology Herlev Denmark
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Infectious Diseases Specialist Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
National Institute for Public Health and the Environment Bilthoven the Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011792
- 003
- CZ-PrNML
- 005
- 20220506125838.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cmi.2021.09.038 $2 doi
- 035 __
- $a (PubMed)34678515
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a van Prehn, Joffrey $u Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- 245 10
- $a European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults / $c J. van Prehn, E. Reigadas, EH. Vogelzang, E. Bouza, A. Hristea, B. Guery, M. Krutova, T. Norén, F. Allerberger, JE. Coia, A. Goorhuis, TM. van Rossen, RE. Ooijevaar, K. Burns, BR. Scharvik Olesen, S. Tschudin-Sutter, MH. Wilcox, MJGT. Vehreschild, F. Fitzpatrick, EJ. Kuijper, Guideline Committee of the European Study Group on Clostridioides difficile
- 520 9_
- $a SCOPE: In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014. The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as faecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, prompted the ESCMID study group on C. difficile (ESGCD) to update the 2014 treatment guidance document for CDI in adults. METHODS AND QUESTIONS: Key questions on CDI treatment were formulated by the guideline committee and included: What is the best treatment for initial, severe, severe-complicated, refractory, recurrent and multiple recurrent CDI? What is the best treatment when no oral therapy is possible? Can prognostic factors identify patients at risk for severe and recurrent CDI and is there a place for CDI prophylaxis? Outcome measures for treatment strategy were: clinical cure, recurrence and sustained cure. For studies on surgical interventions and severe-complicated CDI the outcome was mortality. Appraisal of available literature and drafting of recommendations was performed by the guideline drafting group. The total body of evidence for the recommendations on CDI treatment consists of the literature described in the previous guidelines, supplemented with a systematic literature search on randomized clinical trials and observational studies from 2012 and onwards. The Grades of Recommendation Assessment, Development and Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence. The guideline committee was invited to comment on the recommendations. The guideline draft was sent to external experts and a patients' representative for review. Full ESCMID endorsement was obtained after a public consultation procedure. RECOMMENDATIONS: Important changes compared with previous guideline include but are not limited to: metronidazole is no longer recommended for treatment of CDI when fidaxomicin or vancomycin are available, fidaxomicin is the preferred agent for treatment of initial CDI and the first recurrence of CDI when available and feasible, FMT or bezlotoxumab in addition to standard of care antibiotics (SoC) are preferred for treatment of a second or further recurrence of CDI, bezlotoxumab in addition to SoC is recommended for the first recurrence of CDI when fidaxomicin was used to manage the initial CDI episode, and bezlotoxumab is considered as an ancillary treatment to vancomycin for a CDI episode with high risk of recurrence when fidaxomicin is not available. Contrary to the previous guideline, in the current guideline emphasis is placed on risk for recurrence as a factor that determines treatment strategy for the individual patient, rather than the disease severity.
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a antibakteriální látky $x terapeutické užití $7 D000900
- 650 _2
- $a monoklonální protilátky $7 D000911
- 650 _2
- $a široce neutralizující protilátky $7 D000080908
- 650 _2
- $a Clostridioides difficile $7 D016360
- 650 12
- $a klostridiové infekce $x diagnóza $x farmakoterapie $7 D003015
- 650 _2
- $a fidaxomicin $7 D000077732
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 _2
- $a vankomycin $7 D014640
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Reigadas, Elena $u Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 700 1_
- $a Vogelzang, Erik H $u Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands
- 700 1_
- $a Bouza, Emilio $u Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 700 1_
- $a Hristea, Adriana $u University of Medicine and Pharmacy Carol Davila, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania
- 700 1_
- $a Guery, Benoit $u Infectious Diseases Specialist, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 700 1_
- $a Krutova, Marcela $u Department of Medical Microbiology, Charles University in Prague and Motol University Hospital, Czech Republic
- 700 1_
- $a Norén, Torbjorn $u Faculty of Medicine and Health, Department of Laboratory Medicine, National Reference Laboratory for Clostridioides difficile, Clinical Microbiology, Örebro University Hospital, Örebro, Sweden
- 700 1_
- $a Allerberger, Franz $u Austrian Agency for Health and Food Safety (AGES), Vienna, Austria
- 700 1_
- $a Coia, John E $u Department of Clinical Microbiology, Hospital South West Jutland and Department of Regional Health Research IRS, University of Southern Denmark, Esbjerg, Denmark
- 700 1_
- $a Goorhuis, Abraham $u Department of Infectious Diseases, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands
- 700 1_
- $a van Rossen, Tessel M $u Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands
- 700 1_
- $a Ooijevaar, Rogier E $u Department of Gastroenterology, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands
- 700 1_
- $a Burns, Karen $u Departments of Clinical Microbiology, Beaumont Hospital & Royal College of Surgeons in Ireland, Dublin, Ireland
- 700 1_
- $a Scharvik Olesen, Bente R $u Department of Medical Microbiology, Herlev, Denmark
- 700 1_
- $a Tschudin-Sutter, Sarah $u Department of Infectious Diseases and Infection Control, University Hospital Basel, University Basel, Universitatsspital, Basel, Switzerland
- 700 1_
- $a Wilcox, Mark H $u Department of Microbiology, Old Medical, School Leeds General Infirmary, Leeds Teaching Hospitals & University of Leeds, Leeds, United Kingdom
- 700 1_
- $a Vehreschild, Maria J G T $u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Fitzpatrick, Fidelma $u Department of Clinical Microbiology, Beaumont Hospital, Dublin, Ireland; Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland
- 700 1_
- $a Kuijper, Ed J $u Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Electronic address: e.j.kuijper@lumc.nl
- 710 2_
- $a Guideline Committee of the European Study Group on Clostridioides difficile
- 773 0_
- $w MED00001139 $t Clinical microbiology and infection $x 1469-0691 $g Roč. 27 Suppl 2, č. - (2021), s. S1-S21
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34678515 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125830 $b ABA008
- 999 __
- $a ok $b bmc $g 1789410 $s 1162990
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 27 Suppl 2 $c - $d S1-S21 $e 20211020 $i 1469-0691 $m Clinical microbiology and infection $n Clin Microbiol Infect $x MED00001139
- LZP __
- $a Pubmed-20220425
